The Japanese companies Kidswell Bio Corporation and Chiome Bioscience have announced a business alliance agreement aimed at the co-development of new biosimilars, in an effort to stand out in a domestic market focused on small-molecule drugs.
According to the two businesses, many Japanese pharmaceutical companies have focused their resources on R&D in small-molecule drugs instead of biopharmaceuticals, which led to delays in the local development